Thus, the CNV CCND1/CDKN2A ratio may serve as a guideline to doctors whether this cell cycle-dependent kinase inhibitor, PAL treatment, has beneficial effect to the NPC patient. Here, CDKN2A is linked to nasopharyngeal carcinoma.